Salmonella-based vaccines in the works

Arizona State University researchers have demonstrated that they can make safer and more effective vaccines by using a new class of vaccines known as recombinant attenuated Salmonella vaccines (RASV). The method uses a deactivated version of salmonella to deliver Streptococcus pneumoniae, a bacteria that can cause pneumonia, ear infections, meningitis and bacteremia.

The researchers, led by Dr. Roy Curtiss, chief scientist at Biodesign's Center for Infectious Diseases and Vaccinology, found that mice injected with the engineered salmonella strain produced a strong antibody response and stronger immunity to Streptococcus pneumoniae than the control arm. The research was funded in part by the Bill and Melinda Gates Foundation and was presented in the Journal of Immunology.

"Orally-administered RASVs stimulate all three branches of the immune system stimulating mucosal, humoral and cellular immunity that will be protective, in this case, against a majority of pneumococcal strains causing disease," explained Curtiss in a statement. The vaccine is currently in Phase I trials.

- here's the report

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.